Celgene to buy Abraxis BioScience for $2.9 billion
Celgene Corp., the maker of blood cancer drugs, agreed to buy Abraxis BioScience Inc. for $2.9 billion in cash and stock to acquire a breast-tumor medicine.
GENERAL Electric has agreed to buy molecular diagnostic company Clarient for $580m as it looks to accelerate the development of integrated tools for cancer diagnosis and characterisation.